- Home
- RUBI vs PHIO Comparison
RUBI vs PHIO Comparison
Compare RUBI & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RUBI
- PHIO
- Stock Information
- Founded
- RUBI N/A
- PHIO 2011
- Country
- RUBI Marshall Islands
- PHIO United States
- Employees
- RUBI N/A
- PHIO N/A
- Industry
- RUBI Marine Transportation
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- RUBI Consumer Discretionary
- PHIO Health Care
- Exchange
- RUBI Nasdaq
- PHIO Nasdaq
- Market Cap
- RUBI 10.9M
- PHIO 11.2M
- IPO Year
- RUBI N/A
- PHIO N/A
- Fundamental
- Price
- RUBI $2.70
- PHIO $2.13
- Analyst Decision
- RUBI
- PHIO Strong Buy
- Analyst Count
- RUBI 0
- PHIO 2
- Target Price
- RUBI N/A
- PHIO $9.00
- AVG Volume (30 Days)
- RUBI 1.5M
- PHIO 2.7M
- Earning Date
- RUBI 01-01-0001
- PHIO 08-18-2025
- Dividend Yield
- RUBI N/A
- PHIO N/A
- EPS Growth
- RUBI N/A
- PHIO N/A
- EPS
- RUBI N/A
- PHIO N/A
- Revenue
- RUBI N/A
- PHIO N/A
- Revenue This Year
- RUBI N/A
- PHIO N/A
- Revenue Next Year
- RUBI N/A
- PHIO N/A
- P/E Ratio
- RUBI N/A
- PHIO N/A
- Revenue Growth
- RUBI N/A
- PHIO N/A
- 52 Week Low
- RUBI $2.36
- PHIO $0.97
- 52 Week High
- RUBI $6.69
- PHIO $9.79
- Technical
- Relative Strength Index (RSI)
- RUBI N/A
- PHIO 37.22
- Support Level
- RUBI N/A
- PHIO $2.19
- Resistance Level
- RUBI N/A
- PHIO $2.47
- Average True Range (ATR)
- RUBI 0.00
- PHIO 0.21
- MACD
- RUBI 0.00
- PHIO -0.04
- Stochastic Oscillator
- RUBI 0.00
- PHIO 2.88
About RUBI Rubico Inc. Common Stock
Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.